Articles tagged with Dopaminergic Neurons
Researchers at Tel Aviv University develop a peptide therapy that mimics DJ-1's normal function, protecting dopamine-producing neurons and reducing mobility dysfunctions. The treatment has shown promising results in pre-clinical trials on mice, indicating a viable option for Parkinson's patients.
A study led by neuroscientists at the University of North Carolina at Chapel Hill School of Medicine found that activation of GABA neurons in a specific area of the midbrain inhibits dopamine neuron function, leading to a disruption in reward consumption. This discovery could lead to new mental health therapies.
University of Alabama researchers have identified the neuro-protective capability of the VPS41 gene in both animal models and human neurons, providing a potential step toward developing a new drug treatment for Parkinson's disease. The study found that specific changes in human DNA may impact how VPS41 functions.
Researchers at the University at Buffalo discovered how parkin gene mutations cause Parkinson's disease by studying live human neurons. The study identified potential new drug targets and a screening platform to discover treatments, providing hope for a cure.
Research reveals a molecular partnership between ghrelin receptor and dopamine receptor in brain neurons that regulate appetite, shedding light on the underlying mechanisms of obesity and dopamine signaling disorders. The study suggests potential therapeutic targets with fewer side effects, offering new hope for treating these conditions.
Researchers found that reward prediction error is the result of a complex interplay between dopamine and GABA neurons. The interaction helps calculate reward prediction error, shedding light on how behaviors can be reinforced through normal brain function or by damaging neuron interactions.
Researchers found that NMDA receptors on dopamine neurons are essential for habit formation, allowing brain cells to communicate and increase activity. The discovery provides new direction for therapy to treat diseases like Parkinson's and opens the door to speeding up good habit formation.
Researchers from the University of Pennsylvania have successfully reprogrammed astrocytes into dopamine-producing neurons, a crucial step towards treating Parkinson's disease. The study demonstrates conversion efficiency of up to 18%, paving the way for novel reprogramming strategies to treat Parkinson's disease.
Researchers discovered that eliminating acetylcholine secretion boosted dopamine actions, potentially improving motor symptoms in Parkinson's disease. The study used genetically modified mice to investigate the role of neurotransmitters in the striatum, a region affected by the disease.
Researchers at UCLA found that traumatic brain injury increases risk of Parkinson's disease, with a moderate injury causing a 15% loss of nigrostriatal dopaminergic neurons. Exposure to the pesticide paraquat doubles this risk and accelerates neuronal degeneration.
New research in the FASEB Journal suggests that nicotine can protect dopamine neurons in the brain from Parkinson's disease. The discovery of how nicotine does this may lead to entirely new types of treatments for the disease.
Researchers at Karolinska Institutet discovered that dopamine controls the formation of new neurons in the adult brain by acting as a switch for stem cells. The study used salamanders, which can recover from Parkinson's-like conditions, to understand how dopamine regulates neural regeneration.
A team of researchers has identified a phenomenon known as 'cotransmission,' where brain neurons use two different methods of communication to exchange information. This discovery could lead to a better understanding of the mechanisms behind brain diseases such as schizophrenia, Parkinson's, and depression.
New research suggests that defective regulation of microtubules may be responsible for at least some cases of Parkinson's disease. Microtubule disruption impairs dopamine release, leading to oxidative stress and cell death.
Researchers have identified a previously overlooked brain area, the lateral habenula, as a prime locus of human depression. The area's hyperactivity is linked to depression-like symptoms and may be targeted by deep brain stimulation (DBS) for treatment.
A new compound has shown significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder. The compound, SR-3306, aims to inhibit JNK enzymes that play a key role in neuron survival.
SLU researchers found that DOPAL kills healthy dopamine cells, leading to Parkinson's disease. The study provides a promising new avenue for preventing dopamine neuron loss and progression of the disease.
A Northwestern Medicine study found that stressed dopamine-releasing neurons in the brain die prematurely, triggering Parkinson's disease symptoms. The research suggests that controlling this stress with a drug already approved for high blood pressure may delay disease progression.
Researchers found that brain cells in Parkinson's patients abandon their energy-producing machinery, the mitochondria. Boosting the mitochondria with FDA-approved drugs may prevent or delay the onset of Parkinson's disease.
Researchers at the Buck Institute have used human induced pluripotent stem cells (iPSCs) to treat rodent models of Parkinson's Disease, paving the way for potential cell therapies. The study shows that iPSC-derived dopamine-producing neurons can engraft and ameliorate behavioral deficits in animals with PD.
Scientists at Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. The study found that a genetic mutation linked to Parkinson's causes impaired activity of microRNAs, leading to premature cell death.
A new study reveals that low vitamin D levels can predict the development of Parkinson's disease, with individuals having the lowest levels being three times more likely to develop the condition. Researchers are calling for public health authorities to consider raising the target vitamin D level above the current recommended level.
Scientists have found that activating Retinoid X Receptor (RXR) increases dopamine cell survival in models of Parkinson's disease, providing a novel strategy for treating the condition. The study used two cellular models to explore the neuroprotective function of RXR ligands LG268 and XCT.
Scientists at Garvan Institute of Medical Research developed a mathematical model and microscopy method to reveal mechanisms behind dopamine release. The study found that dopamine release is regulated by factors such as the frequency of nerve impulses, making it possible to develop more effective treatments.
A new study in Cell Metabolism has found that leptin, a hormone produced by fat tissue, influences baseline dopamine levels and our motivation to eat. Leptin-responsive neurons in the brain's lateral hypothalamic area feed into the mesolimbic dopamine system, controlling motivation for food, sex, and other desires.
Research demonstrates single neurons process future rewards, including information about upcoming gains, and prefer advance info over suspense. This finding suggests a revised theory of reward is needed, incorporating information seeking as a cognitive reward.
Research in Drosophila larvae reveals that 5-HT and corazonergic neurons regulate photobehavior, increasing aversion to light during foraging phase. The study provides new insights into the function of 5-HT neurons and mechanisms underlying regulation of larval response to light.
Researchers at Columbia University Irving Medical Center have identified a protein called oct3 that plays a critical role in both Parkinson's disease and addictive drugs. The protein helps toxic chemicals reach dopamine neurons, leading to cell death in patients with Parkinson's disease.
Researchers discover organic cation transporter 3 (oct3) plays a critical role in both Parkinson's disease and drug addiction by transporting toxic chemicals into brain cells that die in patients with the condition. Oct3 helps astrocytes remove excess dopamine, leading to feelings of euphoria but also potential brain damage.
Parkinson's disease is characterized by selective loss of dopamine neurons in the substantia nigra, with elevated cytosolic dopamine and calcium levels contributing to cell death. Genetic and environmental 'hits' are required for PD pathology, suggesting multiple therapeutic targets should be considered
Researchers at Columbia University Medical Center found that dopamine, a calcium channel, and alpha-synuclein act together to kill brain cells in Parkinson's disease. The discovery gives hope for saving neurons and stopping the progression of the disease by targeting just one of the three factors.
Researchers found that precisely tuning oscillation frequencies of certain neurons can affect how the brain processes information and implements feelings of reward. The study suggests that parvalbumin neurons play a crucial role in generating gamma brain waves, which enhance information flow among different cell types.
Researchers found that dopamine neuron bursting activity is crucial for learning rewarding outcomes. The study suggests that the NMDA receptor plays a key role in regulating burst firing in dopamine neurons.
Researchers found that a gene called Nurr1 limits pro-inflammatory neurotoxic mediators in microglia and astrocytes, suggesting a link between inflammation and Parkinson's disease progression. The study may point to new avenues for therapy and anti-inflammatory treatments to combat the disease.
A study by University of California, San Diego researchers identified a protein called Nurr1 that protects neurons from excessive inflammation, which can lead to neurodegenerative disorders like Parkinson's disease. The protein's protective function was found to involve shutting off inflammatory responses in microglia and astrocytes.
Researchers have identified a stage during dopamine neuron differentiation that may be an ideal time to collect human embryonic stem cells for transplantation to treat Parkinson's disease. Lmx1a-positive cells with TrkB surface marker can be selected using magnetic-activated cell sorting or fluorescence-activated cell sorting.
Researchers genetically modified a brain receptor to make it more sensitive to nicotine, allowing them to study the effects of dopamine production on hyperactivity in mice. This could lead to new knowledge about dopamine neurons' functions and potential treatments for conditions such as ADHD.
Researchers at Georgetown University Medical Center have identified a protein, NuIP, that regulates the Nurr1 gene critical to dopamine-releasing brain cells. Loss of NuIP function is linked to decreased numbers of dopamine-producing neurons and a decrease in expression of the dopamine transporter.
Researchers at the University of Cincinnati have found that deep brain stimulation can halt the progression of dopamine-cell loss in animal models. The study suggests that stimulating neurons with electrodes boosts the amount of BDNF, a protein that promotes neuronal growth.
Studies link cocaine-evoked synaptic changes in dopamine (DA) neurons to long-term drug-seeking behavior, highlighting NMDA receptor signaling and glutamate receptor subunit composition. Findings support a role for NMDAR-dependent modulation of DA neurons in cue-induced relapse.
The Parkinson's Disease Foundation has awarded $950,000 in seed grants to 19 researchers, including Matthew Goldberg and Sandra M. Lynch, to explore new treatments for Parkinson's disease. The funding will support the development of animal models and antibody-based therapies.
Scientists have identified 'mother cells' that produce dopamine-producing neurons affected by Parkinson's disease. These radial glia-like cells could be used to grow replacement neurons in the lab, potentially leading to new treatments for the disease.
Researchers discover that FOXA2 specifies the floor plate and induces dopamine neuron birth, leading to motor deficits and degeneration in mice. This study provides insights into dopamine neuron development and offers potential avenues for treating neurodegenerative diseases like Parkinson's.
Researchers at Université Laval discovered that a diet rich in omega-3 fatty acids protects the brain against Parkinson's disease. The study found that mice fed an omega-3 rich diet were immune to the toxic compound MPTP, which causes damage to dopamine-producing neurons.
Researchers found a link between the loss of norepinephrine and dopamine neurons and delayed Parkinson's symptoms. The study showed that both types of neurons are necessary for normal motor function.
In mice and human patients, researchers found that crippling of protective enzyme Prx2 leads to death of dopamine-producing neurons in Parkinson's disease. Activating Prx2 prevents neuronal loss, suggesting it as a beneficial target for PD treatment.
Scientists have discovered a potential new treatment for Parkinson's disease by inhibiting the action of an enzyme called SIRT2. Blocking this pathway is believed to protect neurons damaged in Parkinson's from the toxic effects of alpha-synuclein, a protein that accumulates in the brains of patients.
Researchers have found that Isradipine slows the destruction of dopamine-producing neurons in a mouse model, potentially preventing Parkinson's disease or slowing its progression. The study aims to develop clinical trials in humans to test the drug's efficacy.
Researchers at Northwestern University have discovered a drug that slows and may halt the progression of Parkinson's disease by rejuvenating aging dopamine cells. Isradipine, a widely used hypertension medication, restores stressed-out dopamine neurons to their youthful state, potentially extending the time L-DOPA works effectively.
GST pi is a critical enzyme that stands at the crossroads of several biochemical pathways leading to Parkinson's disease. It prevents both externally provoked cell death and internally initiated suicide by blocking the formation of free radicals, which cause cell damage.
Researchers found that mutations in LRRK2 protein stunt neuron growth and branching, leading to dopamine-producing neuron loss and disease progression. The study provides a useful animal model for studying PD and discovering new treatments.
Researchers have found that ghrelin stimulates the same pleasure and reward neurons as food, sex, and drugs, leading to increased food intake. Ghrelin binds to receptors in the brain's ventral tegmental area (VTA), triggering dopamine production.
Neuroscientists at Duke University Medical Center discovered that critical nerve cells in mice fire all at the same time, overwhelming the brain's ability to control movement. This finding contradicts current theories behind Parkinson's disease and may help develop new therapeutics.
A study by the University of Pittsburgh found that dopamine levels remain elevated for an hour after neurons are stimulated, suggesting new mechanisms for sustained dopamine availability. This could have important implications for treating neurological disorders related to dopamine imbalance.
Researchers found that dopamine plays a critical role in regulating sleep and brain activity associated with dreaming. Animal models of Parkinson's disease and schizophrenia exhibited sleep disturbances when dopamine levels were reduced or increased, suggesting a link between dopamine imbalances and sleep problems in these conditions.
A Yale University study reveals leptin's powerful effect on the brain's reward center, impacting appetite regulation. The hormone suppresses dopamine neurons in the ventral tegmental area, linked to behaviors like obesity, drug addiction, and impulsivity.
UT Southwestern researchers found that blocking tumor necrosis factor, an inflammatory molecule, reduces dopamine neuron death in rats with Parkinson's disease. The study suggests that TNF-dependent inflammation may contribute to the progression of the disease.
Researchers used a genetic tool to activate specific neurons in fruit flies, revealing that two subsets of neurons are responsible for assigning positive or negative values to stimuli. This discovery advances our understanding of how animals learn to associate cues with experiences and has implications for more complex mammalian brains.
Researchers have created a new genetic model for Parkinson's disease using mice with a deleted TFAM gene, which mimics the human condition. The study shows that dopamine-producing nerve cells in the brain stem degenerate slowly, similar to humans with Parkinson's disease.
Researchers discovered a dopamine drug that stimulates new neuron development and restores function in an animal model of Parkinson's disease. The treatment, 7-OH-DPAT, led to significant improvements in motor functions and neuronal connections.